Physician profile
Danielle Carr
NPI 1043787013
$4,980.92
in general payments reported to CMS, 2019-2025
32 companies · $849 in 2025
The $849 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,093 · 2022: $752 · 2023: $1,116 · 2024: $1,171 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.76 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.39 | 2021-2025 | |
| Lilly USA, LLC | $809.87 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $624.56 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $483.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $459.70 | 2021-2025 | Airsupra, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.19 | 2021-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $165.29 | 2021-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $157.90 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $156.67 | 2021-2025 | Eohilia |
| Amgen INC. | $125.44 | 2021-2025 | Repatha, Otezla, Tezspire |
| Janssen Pharmaceuticals, INC | $96.46 | 2025 | Spravato |
| Exact Sciences Corporation | $94.70 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $93.67 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $78.60 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $66.67 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.68 | 2022 | |
| Nevro Corp. | $44.16 | 2022 | |
| Medtronic, INC. | $40.07 | 2021-2022 | |
| Tolmar, INC. | $33.63 | 2024 | |
| Orexo US, INC. | $30.56 | 2022-2024 | Zubsolv |
| Biohaven Pharmaceuticals, INC. | $29.21 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.58 | 2023 | Givlaari |
| Seqirus USA INC | $18.85 | 2025 | Flucelvax, Fluad |
| Sanofi-Aventis U.S. LLC | $18.50 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $18.08 | 2023 | Seglentis |
| Bioventus LLC | $17.38 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.07 | 2021 | |
| Dexcom, INC. | $15.97 | 2022 | |
| Shield Therapeutics INC | $14.15 | 2025 | |
| Currax Pharmaceuticals LLC | $14.09 | 2023 | Contrave |
| Adlon Therapeutics L.P. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.